Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring

CONCLUSION: In this phase II randomized trial, adavosertib improved PFS compared with AM and demonstrates potential as a well-tolerated therapy for RAS/TP53-mutant mCRC. Further testing is required in this sizable population of unmet need.PMID:34538072 | DOI:10.1200/JCO.21.01435

Source: Clinical Colorectal Cancer - September 20, 2021 Category: Cancer & Oncology Authors: Jenny F Seligmann David J Fisher Louise C Brown Richard A Adams Janet Graham Philip Quirke Susan D Richman Rachel Butler Enric Domingo Andrew Blake Emma Yates Michael Braun Fiona Collinson Rob Jones Ewan Brown Emma de Winton Timothy C Humphrey Mahesh Parm Source Type: research